TY - JOUR
T1 - Dysregulated cholesterol metabolism, aberrant excitability and altered cell cycle of astrocytes in fragile X syndrome
AU - Ren, Baiyan
AU - Burkovetskaya, Maria
AU - Jung, Yoosun
AU - Bergdolt, Lara
AU - Totusek, Steven
AU - Martinez-Cerdeno, Veronica
AU - Stauch, Kelly
AU - Korade, Zeljka
AU - Dunaevsky, Anna
N1 - Publisher Copyright:
© 2023 The Authors. GLIA published by Wiley Periodicals LLC.
PY - 2023/5
Y1 - 2023/5
N2 - Fragile X syndrome (FXS), the most prevalent heritable form of intellectual disability, is caused by the transcriptional silencing of the FMR1 gene. While neuronal contribution to FXS has been extensively studied in both animal and human-based models of FXS, the roles of astrocytes, a type of glial cells in the brain, are largely unknown. Here, we generated a human-based FXS model via differentiation of astrocytes from human-induced pluripotent stem cells (hiPSCs) and human embryonic stem cells (hESCs) and characterized their development, function, and proteomic profiles. We identified shortened cell cycle, enhanced Ca2+ signaling, impaired sterol biosynthesis, and pervasive alterations in the proteome of FXS astrocytes. Our work identified astrocytic impairments that could contribute to the pathogenesis of FXS and highlight astrocytes as a novel therapeutic target for FXS treatment.
AB - Fragile X syndrome (FXS), the most prevalent heritable form of intellectual disability, is caused by the transcriptional silencing of the FMR1 gene. While neuronal contribution to FXS has been extensively studied in both animal and human-based models of FXS, the roles of astrocytes, a type of glial cells in the brain, are largely unknown. Here, we generated a human-based FXS model via differentiation of astrocytes from human-induced pluripotent stem cells (hiPSCs) and human embryonic stem cells (hESCs) and characterized their development, function, and proteomic profiles. We identified shortened cell cycle, enhanced Ca2+ signaling, impaired sterol biosynthesis, and pervasive alterations in the proteome of FXS astrocytes. Our work identified astrocytic impairments that could contribute to the pathogenesis of FXS and highlight astrocytes as a novel therapeutic target for FXS treatment.
UR - http://www.scopus.com/inward/record.url?scp=85145418837&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85145418837&partnerID=8YFLogxK
U2 - 10.1002/glia.24331
DO - 10.1002/glia.24331
M3 - Article
C2 - 36594399
AN - SCOPUS:85145418837
SN - 0894-1491
VL - 71
SP - 1176
EP - 1196
JO - Glia
JF - Glia
IS - 5
ER -